YouTube video by Noxopharm

ASX BRIEFS · Episode

YouTube video by Noxopharm

Targeting Toll-like receptor 7 (TLR7) represents a promising therapeutic strategy for the treatment of systemic lupus erythematosus (SLE). This Review provides mechanistic insights into the roles of T...

Noxopharm Limited CEO Olivier Laczka talked with Proactive about the company's Sofra™ technology platform and how its discovery around Toll-like...

A study from the Gantier lab (Hudson Institute/Monash University), published in Nature Immunology, reveals that naturally occurring 2′-O-methyl-guanosine RNA fragments act as potent antagonists of TLR7 and TLR8, binding a previously unknown site to keep the receptors in an inactive state.

The Future of mRNA Is Being Built in APAC

It's one of medicine's biggest mysteries — why sometimes our immune system attacks our own bodies. Autoimmune diseases affect as many as 50 million Americans and millions more worldwide.

Melbourne researchers have developed a new RNA drug designed to prevent the damaging effects of the debilitating autoimmune disease lupus, in a major breakthrough supported by the Allan Labor Governme...

The Nobel Prize in Physiology or Medicine 2025 was awarded jointly to Mary E. Brunkow, Frederick J. Ramsdell and Shimon Sakaguchi "for their discoveries concerning peripheral immune tolerance"

After a strategy revamp Noxopharm is pursuing a clinical program targeting inflammation, notably the painful condition skin lupus.